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ABSTRACT CARET is a chemoprevention trial of 13-carotene and vitamin A with lung cancer 
as the primary outcome. Participants at high risk for lung cancer are drawn from two 
populations: asbestos-exposed workers and heavy smokers. The intervention is a daily 
combination of 30 mg 13-carotene and 25,000 IU vitamin A as retinyl palmitate. Nearly 
18,000 participants will be followed for a mean 6 years, yielding over 100,000 person- 
years of follow-up. We project that this sample size will have 80% power to detect a 
23% decrease in the incidence of lung cancer cases. 
The purpose of this paper is to present he values of the key sample size parameters 
of CARET; our schemes for monitoring CARET for sample size adequacy, incidence 
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of side effects, and efficacy of the study vitamins; an overview of the data collected; 
and plans for the primary, secondary, and ancillary analyses to be performed at the 
end of the trial. These approaches tothe design, monitoring, and analysis of CARET 
are applicable for many other prevention trials. 
KEY WORDS: chemoprevention, lung cancer, sample size, monitoring rules 
INTRODUCTION 
The Carotene and Retinol Efficacy Trial (CARET) is a randomized, double- 
masked, placebo-controlled investigation of the safety and efficacy of [3-car- 
otene and vitamin A in decreasing the incidence of lung cancer in two pop- 
ulations at high risk: asbestos-exposed workers and heavy smokers [1,2]. 
Eligible asbestos-exposed participants are men who are aged 45-69, are cur- 
rent cigarette smokers or have quit within the previous 15 years, have oc- 
cupational exposure to asbestos beginning at least 15 years previously, and 
have had significant occupational exposure to asbestos or have chest X rays 
positive by International Labour Organization criteria for changes consistent 
with asbestos-related disease. Recruitment of asbestos-exposed participants 
was restricted to men only because there were very few women in trades 
with high asbestos exposure more than 15 years ago. Eligible heavy smokers 
are both men and women who are aged 50-69, are current smokers or have 
quit within the previous 6 years, and have 20 or more pack-years of cigarette- 
smoking history. Participants are seen at six study centers: Baltimore, Mary- 
land; Irvine, California; New Haven, Connecticut; Portland, Oregon; San 
Francisco, California; and Seattle, Washington. Prior to randomization, par- 
ticipants complete a 3-month run-in period receiving placebo medication to 
determine their adherence to taking the study vitamins and their baseline 
levels of symptoms, signs, and liver function tests. Participants who take at 
least 50% of their study vitamins (as determined from weights of returned 
capsule bottles) and are still eligible are randomized to a daily combination 
of 30 mg (50,000 IU) 13-carotene and 25,000 IU retinol (as retinyl palmitate) 
dispensed in a single capsule or to a comparable capsule containing placebo 
medication. Randomization is by household, stratified by population (asbes- 
tos-exposed participants and heavy smokers) and study center, using blocked 
randomization with random block size to ensure balance of follow-up time 
in the two arms. Households are randomized because of the possibility of 
participants taking capsules from their spouses' bottles. 
In the first year after randomization, participants are contacted twice by 
telephone (at 3 and 9 months after andomization) and visit twice at the study 
center (at 6 and 12 months). Subsequently, participants are contacted twice 
by telephone and once at a study center visit each year. At each contact here 
is monitoring for possible toxicity, reflected in symptoms, signs, or laboratory 
values potentially attributable to the study vitamins. 
CARET builds on the experience of two pilot studies performed in Seattle 
(1985-1988) that demonstrated that the recruitment strategies could accrue 
targeted numbers of participants, that adherence both to taking the study 
vitamins and to the data collection schedule was excellent, and that side effects 
were few. The first pilot study initiated a phase III trial of the safety and 
efficacy of the study vitamins in 816 asbestos-exposed participants random- 
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ized to a daily combination of 15 mg 13-carotene and 25,000 IU retinol or a 
placebo medication [3]. Participants were eligible up to age 74 and were not 
required to have a history of cigarette smoking; otherwise, the eligibility 
criteria were the same as for the asbestos-exposed population in CARET [1]. 
The second pilot study was a phase II trial of the comparative safety of the 
study vitamins in heavy smokers [4]. The eligibility criteria were identical to 
those for heavy smokers in CARET. We randomized 539 men and 490 women 
to one of four intervention groups: a daily combination of 30 mg 13-carotene 
and 25,000 IU retinol; 30 mg 13-carotene only; 25,000 IU retinol only; or placebo 
medication. All 1845 participants in the two pilot studies continue to be fol- 
lowed for outcomes in CARET, together with approximately 16,000 additional 
participants, called "efficacy" participants, whom we are currently recruiting. 
With the expansion to the full-scale trial, all participants in the pilot studies 
who were receiving any active vitamins had their dosages changed, where 
necessary, to match the dosage used in CARET. Only those originally ran- 
domized to placebo medication continue to receive placebo medication. As a 
result, three fourths of the participants from the pilot study in heavy smokers 
are in the group randomized to receive active vitamins. Participants from the 
pilot studies are monitored more closely for indications of toxicity than are 
the efficacy participants, since due to their longer follow-up time toxicities 
related to cumulative dose should appear in them years before they would 
appear in the efficacy participants. 
The primary trial outcome is lung cancer. Secondary outcomes are malig- 
nant mesothelioma (in the asbestos-exposed population), other malignancies, 
and death. Since we do not anticipate that vitamin A and 13-carotene will be 
effective against existing lung tumors, we down-weight lung cancers diag- 
nosed in the first 2 years after randomization. The primary analysis of the 
effectiveness of the study vitamins will involve a comparison between the 
intervention groups of the numbers of weighted lung cancers, with weight 
function w(t) = min(t/2,1), where t is the time in years since randomization 
at which the lung cancer is diagnosed. To achieve adequate power to test the 
effect of vitamin A and 13-carotene on the number of weighted lung cancers, 
CARET has a goal of randomizing approximately 17,700 participants. 
The purpose of this paper is to present he key parameters of the statistical 
design of CARET, as a guide to researchers designing other chemoprevention 
trials. We detail the determinants of the number of participants needed and 
the duration of the trial, describe our four schemes for monitoring progress, 
and outline the data collected and the analyses planned. 
ESTIMATION OF SAMPLE SIZE AND TRIAL DURATION 
The estimation of sample size requires the specification of the incidence of 
the trial outcome (lung cancer), adherence to taking the study vitamins, and 
rate of loss to follow-up, together with statistical parameters. Table I presents 
the values of the sample size parameters utilized in the design of CARET and 
reported by Omenn et al. [1]. These values reflect our review of the relevant 
literature and our pilot study experiences [3,4]. 
We developed models for the incidence rate of lung cancer as a function 
of risk factors (age, gender, smoking history, and asbestos exposure) in the 
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Table 1 Parameters Used in the Sample Size Calculations for CARET 
Initial Values" Updated Values b
Lung cancer ate (per 10 s) 0 yr 8 yr 
Pilot asbestos 600 1100 
Efficacy asbestos 800 1300 
Smokers 300 600 
Capsule consumption rate, active 0 yr 3 yr 
vitamin group 
Pilot asbestos 100% 80% 
Pilot smokers 100% 67% 
Efficacy asbestos 100% 80% 
Efficacy smokers 100% 67% 
Maximum supplementary vitamin 0 yr 3 yr 
intake, placebo medication 0% 5% 
group 
MPCE c 33% 
Time lag to full effectiveness 2 years 
Loss to competing risks 
Death rate (per 10 s) 0 yr 8 yr 
Pilot asbestos 1900 2600 
Efficacy asbestos 1900 2600 
Smokers 1500 2500 
Loss to follow-up 2% over trial 
Duration of accrual period 
Pilots 3 years 
Efficacy 5 years 
Type I error .05 two-sided 
Power 80% 
Number of participants 4,277 Asbestos 
13,629 Smokers 
17,906 Total 
8 yr 
75% 
62% 
75% 
62% 
8 yr 
5% 
0 yr 8 yr 
3OO 5OO 
80O 1000 
4OO 6O0 
0 yr 3 yr 
98% 73% 
98% 67% 
94% 85% 
95% 79% 
0 yr 3 yr 
0% 5% 
33% 
2 years 
0 yr 8 yr 
1000 2000 
900 1700 
700 1600 
2% over trial 
3 years 
Table 3 
.05 two-sided 
8O% 
3,983 Asbestos 
13,719 Smokers 
17,702 Total 
8 yr 
64% 
58% 
7O% 
54% 
8 yr 
5% 
"Reproduced from Omenn et al. [1]. 
~Based on monitoring of the duration required for desired power through June 1992 (see text). 
CMaximal potential chemopreventive effect, the reduction in risk in fully adherent participants 
on the active vitamins compared to placebo. 
absence of an intervention using 1981-1985 lung cancer incidence rates by 
age and gender from the Surveillance, Epidemiology, and End Results Pro- 
gram [5]; relative risks for current smokers to never-smokers and to former 
smokers by gender from the American Cancer Society's CPS-II study [6]; and 
distributions of lung cancer risk factors by age and gender in the U.S. from 
the 1985 National Health Interview Survey [7] and the 1986 Adult Use of 
Tobacco Survey [8]. We used a relative risk of 3 for the effect of asbestos- 
exposure, based on other studies in similar populat ions [9-11]. The lung 
cancer incidence rates expected in the CARET participants were projected 
from these models using the distributions of risk factors in the randomized 
participants. Lung cancer and death rates increase by time since randomi- 
zation due to the aging of the study participants. 
Adherence to taking the study vitamins is operationally measured by the 
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mean number of capsules of study vitamins taken per day by participants 
(called the capsule consumption rate). The mean is over all participants who are 
still alive, including those who have stopped taking study vitamins for any 
reason, and is based on weights of returned bottles of study vitamins and on 
self-reports when bottle weights are not available. Capsule consumption rates 
for the first 3 years after randomization (Table 1) were based on experience 
from the pilot studies. These rates were similar to those reported for three 
large cardiovascular t ials with cholesterol-lowering drugs [12], aspirin [13], 
and [3 blockers [14]. We projected a decline in the capsule consumption rate 
of 1% per year for years 3-8, based on the decline seen in later years in the 
Lipid Research Clinics trial [12]. 
The CARET design allows for participants in the group receiving placebo 
medication to be taking up to an equivalent of 5% of the specified ose through 
intake of supplementary vitamins. We expect his factor to be conservative; 
through June 1992 less than 1% of participants were taking supplemental 
vitamin A over 5,500 IU/day or any 13-carotene. 
We planned CARET with the view of being able to examine the potential 
efficacy of vitamin A and ~-carotene in two high-risk populations: asbestos- 
exposed workers and heavy smokers. Our target was to have 80% power to 
detect a 33% maximal potential chemopreventive effect (MPCE) in the total 
study population and a 50% MPCE in each subpopulation (asbestos-exposed 
participants and heavy smokers) separately. The MPCE is defined to be the 
reduction in lung cancer isk in the intervention arm if all participants in both 
arms were fully adherent. Because of the time lag to full effectiveness and 
the allowance for less than full adherence of the trial participants, the actual 
observable reductions will be less than the MPCE. 
We developed models for the incidence rate of death in the absence of an 
intervention as a function of relevant risk factors (age, gender, smoking his- 
tory, and asbestos exposure) from 1980 U.S. total mortality by age and gender 
[16]; relative risks for current smokers to never-smokers and to former smokers 
by gender from the U.S. Surgeon General's report [17]; and the distributions 
of lung cancer risk factors in the United States used above in the modeling 
of lung cancer incidence rates. Total mortality among CARET participants 
was projected, and then the lung cancer incidence rate determined above was 
subtracted to estimate the loss to causes of death other than lung cancer. 
Lung cancer incidence is a good approximation to lung cancer mortality be- 
cause of low survival after the diagnosis of lung cancer--less than 15% after 
5 years [5]. 
We established study centers in five regions with major cohorts of asbestos- 
exposed shipyard workers (Baltimore, New Haven area, Portland, and San 
Francisco, in addition to the original study center in Seattle) and, based on 
pilot experience of response to recruitment efforts, set requirement targets of 
4277 randomized asbestos-exposed participants (including the participants 
from the pilot study in asbestos-exposed workers). We targeted the accrual 
of 13,629 heavy smokers (including the participants from the pilot study in 
heavy smokers) at study centers in Irvine, Portland, and Seattle. For this 
sample size, given the parameters outlined in Table 1, the duration of follow- 
up needed to achieve our desired power was 7.8 years from the first ran- 
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domizations to the efficacy cohort in June 1989. Allowing an additional 6 
months of follow-up for reporting lags, follow-up would conclude in Septem- 
ber 1997, if all these projections were met. 
Although the sample size estimate depends on a large number of factors 
(Table 1), our estimates have been robust across the alternatives that we have 
explored. The product of the sample size and duration of the trial, approxi- 
mately 100,000 person-years of follow-up, depends primarily on the incidence 
rate of lung cancer in the group receiving placebo medication and on the 
anticipated reduction in the incidence rate of lung cancer esulting from our 
intervention. The incidence rate in the group receiving placebo medication 
depends on the distribution of risk factors in that group. The anticipated 
reduction in the incidence rate is influenced by the amount of study vitamins 
received (measured by the capsule consumption rate) and the time lag to full 
effectiveness. The number of person-years i  insensitive to changes in the 
accrual schedule or loss to competing risks. The other factors in Table 1 are 
considered fixed for CARET. 
Smoking cessation has been estimated to have only a small effect on sample 
size. Under the incidence rate models developed for the CARET sample size 
estimation, even if 10% of currently smoking participants stopped smoking 
each year with no relapse, the duration of the trial would change by only 1 
month. Life table estimates of the net reduction (quitters minus relapsers) in 
the number of efficacy participants who are current smokers, based on self- 
reports of smoking behavior through June 1992, are about 6% per year in 
both populations. Thus, the current rate of reduction in smoking observed 
in CARET has negligible ffect on the expected uration of the trial. Assistance 
with smoking cessation is a standardized procedure in CARET. 
MONITORING 
Large prevention trials such as CARET must be monitored closely to justify 
the investment of the sponsoring agency. It is important to demonstrate hat 
the trial is progressing as planned, or, if it is not, to identify how to make 
timely changes. In addition to the conduct of cost analyses described in the 
accompanying paper [18], we monitor the progress of CARET in four ways 
(Table 2). The distribution of risk factors, adherence to taking the study vi- 
tamins, and the overall incidence rate of lung cancer are monitored to deter- 
mine whether the initial design assumptions are being met; if not, the duration 
of the trial is adjusted to ensure that the trial maintains the desired power. 
Symptoms, signs, and abnormal laboratory results potentially attributable to 
f3-carotene and retinol are monitored to determine whether our dosage of the 
study vitamins results in toxicity, which if greater than any potential benefit 
of the study vitamins in preventing cancer could result in termination of the 
trial with the conclusion of no net benefit. The difference between the groups 
receiving active and placebo medication i  the incidence rates of lung cancer 
is monitored so that the trial may be stopped early if there is sufficient evidence 
of efficacy of the study vitamins. Finally, if requested by the Safety and 
Endpoints Monitoring Committee (SEMC) of CARET, the conditional power 
of the trial will be monitored; if low, the trial may be terminated with the 
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Table 2 CARET Monitoring Schemes 
M.D. Thornquist et al. 
Factor 
Monitored Reason Frequency Scheme 
Lung cancer isk Ensure power is Twice per year Input updated values 
factors in maintained into sample size 
randomized formulas 
population 
Incidence of Ensure safety of Twice per year Review by external 
potential side participants, quantify Safety and 
effects side effects due to Endpoints 
vitamins, stop study Monitoring 
if serious problem of Committee (SEMC) 
side effects 
Lung cancer Stop study early if Interim analyses at O'Brien-Fleming 
incidence strong evidence of 1/3 and 2/3 of boundaries [25] 
efficacy weighted" endpoints 
Conditional Stop study if low power As requested by Stochastic 
power for demonstrating SEMC curtailment [26] 
efficacy 
aWeighted by w(s) = min (sly, 1), where sis the time since randomization a d y is the time lag to full 
effectiveness (2 years). 
conclusion of no evidence of efficacy of the study vitamins. These four mon- 
itoring schemes are described below. 
Monitoring Duration Required for Desired Power 
The duration of CARET depends on the rate of recruitment, the incidence 
rates of lung cancer and death in the study population, and the amount of 
study vitamins taken by participants. The sample size calculations outlined 
in the previous section used estimates of these factors based on our pilot 
study experience and experience from other prevention trials. Every 6 months, 
we update the sample size calculation using baseline information from the 
growing number of randomized participants: actual accrual schedule, mean 
age, mean number of cigarettes smoked per day, and mean number of years 
since quitting smoking for former smokers. We also update capsule con- 
sumption rates estimated from weights of returned vitamin bottles and self- 
reports, and examine the rates of lung cancers and deaths in the study pop- 
ulation. We do not analyze the reduction in the incidence rate of lung cancer 
resulting from our intervention i order to avoid the need for adjustment for 
multiple tests. The estimated uration of the trial is recomputed, and the 
results are reviewed by the CARET principal investigators for any effect on 
trial plans, including budgets. 
As an example of the results of this monitoring in CARET, the right column 
of Table 1 presents the trial design parameters updated through June 1992. 
The lung cancer incidence rates in asbestos-exposed participants, capsule 
consumption rates, death rates, and numbers of participants all were revised 
from the original parameters. We have had to increase the planned duration 
of CARET by 0.5 year in order to maintain our power at 80% to detect he 
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alternative hypothesis. The effects of each individual change are described 
below. 
The lung cancer incidence rate in asbestos-exposed participants was lower 
than projected, at least in part due to the removal of prevalent cases by the 
chest X-ray screening for asbestos-related changes performed prior to ran- 
domization (14 cases confirmed and 7 possible). As of June 1992 the observed 
lung cancer incidence rates were 45% of that projected for efficacy asbestos- 
exposed participants and 75% of that projected for the participants from the 
pilot study in asbestos-exposed workers, who had had longer follow-up. For 
the updated values in Table 1, we adjusted the lung cancer rates for the 
asbestos-exposed participants, o that by the end of the trial the observed 
rate would be 80% of the originally projected rates. We expect his projection 
to be conservative. This change increased the projected uration of the trial 
by 0.6 year. 
The capsule consumption rates were updated using observed rates for 
initial years and projecting future years assuming a linear decline using the 
slope observed in the last year for which we have data (rather than the 1%- 
per-year decline for years 3-8 originally assumed). We expect hat the rate of 
decline will decrease in future years of the trial, so the assumption of linear 
decline is conservative. The capsule consumption rates at the time of ran- 
domization reflect he actual rates observed uring the 3-month enrollment 
period with placebo medication prior to randomization. The changes in cap- 
sule consumption rates decreased the projected trial duration by 0.2 year; the 
observed rates in the first years after randomization have been higher than 
originally projected, which offset the eventually lower rates resulting from 
the linear projection. 
Through June 1992, rates of death in the study population were 60% of 
projected; the study population actually had a lower death rate than the entire 
U.S. population for the trial's age range, even though all trial participants 
had asbestos exposure and/or a history of cigarette smoking. A likely expla- 
nation is a healthy volunteer effect. A reduction of the same magnitude, with 
several more years of follow-up, has been observed in the Alpha-Tocopherol 
Beta-Carotene chemoprevention trial in smokers being conducted in Finland 
(personal communication). Thus, we expect hat the lower rates of death may 
persist for the duration of the trial. In Table 1, the projected eath rates have 
been multiplied by 0.6; this decreased the projected uration of the trial by 
0.2 year. 
Changes through June 1992 in the accrual schedules for asbestos-exposed 
participants included a slower rate of accrual than originally planned and a 
reduced target for one study center because of poor response to recruitment 
efforts, but the other four study centers exceeded their accrual targets. Changes 
in the accrual schedules for heavy smokers include a slower rate of accrual 
than originally planned and the addition of recruitment of smoker-eligible 
spouses at the study centers that originally randomized only asbestos-exposed 
participants. These changes increased the projected uration of the trial by 
0.3 year. The accrual for each CARET study center (actual through June 1992 
and targets thereafter) is presented in Table 3. 
Based on the parameters evised in June 1992, the projected uration of 
CARET is 8.3 years from the first randomization; with 6 additional months 
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T a b l e  3 CARET Accrual Schedules 
M.D. Thornquist et al. 
Year of Randomization 
85- 86- 87- 88- 89- 90- 91- 92- 93-- 94- 
Study Center 86 a 87 88 89 90 91 92 93 94 95 Total 
Asbestos-Exposed Workers 
Baltimore . . . .  187 454 165 - -  
New Haven . . . .  267 385 238 110 
Portland . . . .  23 98 100 69 
San Francisco . . . .  206 291 253 120 
Seattle pilot 190 444 182 . . . . .  
Seattle efficacy . . . .  14 23 119 45 
Total b 190 444 182 - -  697 1,251 875 344 
Heavy Smokers 
Baltimore . . . . . . .  3(Y 
Irvine . . . . . .  328 1,820 
New Haven . . . . . . .  3(Y 
Portland - -  - -  - -  67 778 1,295 998 862 
San Francisco . . . . . . .  3(Y 
Seattle pilot 378 499 152 . . . . .  
Seattle efficacy - -  - -  - -  50 1,205 690 1,456 899 
Total b 378 499 152 117 1,983 1,985 2,782 3,671 
F 8O6 
- -  1,000 
- -  290 
- -  870 
- -  816 
- -  201 
- -  3,983 
- -  - -  30 
1,986 166 4,300 
- -  - -  30  
- -  - -  4,000 
- -  - -  30 
- -  - -  1 , 0 2 9  
- -  - -  4,300 
1,986 166 13,719 
aYears run from July to June to match funding schedule. 
bData from 85--86 through 91-92 are actual accruals of randomized participants; later periods are target 
numbers. 
'Additional recruitment decided on in 1992 as a retention i itiative, inviting smoker-eligible spouses in the 
asbestos-only study centers. 
T a b l e  4 Projected Person-years of Fo l low-up and Numbers  of Lung  Cancers  for 
CARET 
Active Vitamin Group Placebo Medication Group 
Numbers of Numbers of 
Person- Numbers Weighted" Person- Numbers Weighted 
Population and years of of Lung Lung years of of Lung Lung 
Cohort Follow-up Cancers Cancers Follow-up Cancers Cancers 
Pilot asbestos 4,000 16 15 4,000 20 18 
Pilot smokers b 7,800 31 28 2,600 13 12 
Efficacy asbestos 9,700 65 54 9,700 85 73 
Efficacy smokers 34,400 113 92 34,300 144 121 
Total 55,900 225 189 50,600 262 224 
aWeighted by w(s) = min (sly, 1) where s is the time since randomization a d y is the time lag to full 
effectiveness (2years). 
bPilot smokers are randomized 3/4 to active, 1/4 to placebo capsules; all other subgroups are randomized 
1/2 to active, 1/2 to placebo. 
for report ing and  conf i rming of lung  cancers, fo l low-up is p lanned to conc lude 
in Apri l  1998. Table 4 presents  the projected person-years  of fo l low-up and  
numbers  of lung  cancers expected. Table 5 presents  the ant ic ipated reduct ions  
in lung  cancer inc idence,  rang ing  from 21% in the pilot heavy smokers  to 
25% in the pilot asbestos-exposed part ic ipants.  The observable chemopre-  
vent ive  efficacy is reduced from the 33% MPCE (Table 1) by our  assumpt ions  
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Table 5 Projected Chemopreventive Effect to be Achieved in CARET 
317 
Population and All Lung Weighted 
Cohort Cancers (%) Lung Cancers (%) 
Pilot asbestos 21 22 
Pilot smokers 19 20 
Efficacy asbestos 23 26 
Efficacy smokers 22 24 
Total 22 23 
about the capsule consumption rates and the time lag to full effectiveness. 
For the two high-risk populations, CARET is projected to be able to detect a 
50% MPCE with 85% power in the asbestos-exposed participants alone and 
with 89% power in the heavy smokers alone. 
The power of this trial to detect reductions in the rate of death from all 
causes likewise depends on the assumed time lag to full effectiveness. CARET 
would have 80% power to detect an MPCE for the death outcome of 17% if 
the effect of the study vitamins on the risk of death were immediate; 19% if 
the time lag is 2 years; and 21% if the time lag is 4 years. To detect a reduction 
in the rate of mesothelioma with a power of 80%, we estimate that the MPCE 
would have to be 58%, based on an estimated incidence rate of 6 per 1000 
person-years and a time lag of 2 years. 
Other outcomes of interest include prostate cancer and atherosclerotic dis- 
ease. Virtamo and Huttunen [19] concluded that the data on the association 
between dietary ~-carotene or vitamin A and prostate cancer are equivocal, 
with some studies suggesting a protective ffect and some an adverse ffect. 
CARET has an 80% power to detect a 36% reduction or a 44% increase in the 
incidence of prostate cancer, assuming a time lag of 2 years. Ridker et al. [20], 
in an abstract of preliminary findings from the Physidans Health Study, 
advocated a prospective trial of ~-carotene for atherosclerotic outcomes; CARET 
has 80% power to detect a19% MPCE on the incidence of myocardial infarction 
plus sudden cardiac death, assuming no time lag. 
Monitoring for Side Effects 
Large doses of retinol may lead to hypervitaminosis A, resulting in skin 
changes, psychological ffective disorders, bone pain, and liver damage [21]. 
The safety of chronic doses of 25,000 IU/day must be investigated, to extend 
the experience from the pilot studies [3,4]. There are case reports of hyper- 
vitaminosis A in adults at doses as low as 25,000 IU per day 7-10 years [22,23]. 
The only known side effect of ~-carotene is yellowing of the skin [24]. 
The CARET protocol includes monitoring all participants for 13 symptoms 
or signs that may be indicative of vitamin A toxicity at each contact [1], and 
monitoring serum levels of glutamic-oxaloacetic transaminase (GOT), alkaline 
phosphatase, total cholesterol, and triglycerides annually in participants con- 
tinuing from the pilot studies. Symptoms that exceed predefined levels of 
severity are managed with a scheme that includes topping the study vitamins 
and rechallenging [4]. 
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Every 6 months the CARET Coordinating Center analyzes the accumulated 
data on symptoms, signs, and laboratory values and reports the results by 
coded intervention group to the SEMC. Analyses of data from active partic- 
ipants compare mean symptom grades and percentages above threshold grades; 
analyses of data from participants who have stopped taking the study vitamins 
(called "inactive" participants) examine reasons for and time course to be- 
coming inactive, and means and maximum symptom grades immediately 
prior to becoming inactive. Through June 1992, differences between the in- 
tervention groups were negligible. In the event the differences become sig- 
nificant, the SEMC may recommend additional analyses and/or changes in 
the trial. We have not set up formal monitoring rules for side effects because 
of the large number monitored. A rule based on a combined score across all 
symptoms and signs monitored would not be sensitive to large differences 
in any one symptom or sign, while separate rules for each symptom and sign 
would result in extreme stopping boundaries because of multiple testing. The 
SEMC prefers to synthesize the information on symptoms and signs with 
evidence of efficacy in deciding by formal vote whether to continue the trial 
at each semiannual meeting. 
Monitoring of Outcomes 
Outcomes in CARET are lung cancer, mesothelioma, other cancers (except 
nonmelanoma skin cancers), and death. Sources of initial reports of outcomes 
are trial participants or their next of kin, cancer registries, state boards of 
health, and the National Death Index. All initial reports of outcomes are 
reviewed by CARET's internal endpoints committee to determine whether 
they are indeed study outcomes. Slides and specimens from all tumors with 
lung involvement are reviewed by CARET's consulting pathologist (S.H.), a 
specialist in pulmonary immunopathology and mesotheliomas. For each can- 
cer, the committee comes to a decision on the primary site, histology, date 
of histological diagnosis, and relationship of the cancer to death if the par- 
ticipant has died. For each death, the committee decides on the cause (im- 
mediate and underlying), date of death, and whether cancer was present at 
death. Details on all outcomes, both confirmed and pending confirmation, 
are reported semiannually to the SEMC. 
The formal CARET monitoring for stopping the trial due to demonstrated 
efficacy of the study vitamins is provided by O'Brien-Fleming boundaries 
[25]. Interim analyses will be performed at one third and two thirds of the 
projected number of weighted lung cancers. Using O'Brien-Fleming bound- 
aries, there is little probability of stopping early unless there is strong evidence 
of efficacy of the study vitamins, since we also need to establish the safety 
of long-term supplementation at the trial dosage. The critical p values are 
.0006 for the first interim analysis, .015 for the second, and .047 for the final 
analysis [25]. Based on experience through June 1992, we project that one 
third of the weighted outcomes will occur by January 1994 and two thirds by 
January 1996. Allowing 6 months for reporting and confirming lung cancer 
outcome cases, we expect o perform the scheduled interim analyses in the 
summers of 1994 and 1996. 
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Monitoring of Conditional Power 
In addition to stopping the trial for toxicity or for efficacy, we allow for 
stopping the trial because of the absence of a difference between the inter- 
vention groups in the inddence of lung cancer. We will use the method of 
stochastic curtailment [26], in which the power for detecting the desired effect 
at the end of the trial is computed under the alternative hypothesis conditional 
on the data to date. Such computations will be performed at the request of 
the SEMC. We have no formal stopping boundaries because the decision on 
whether to continue the trial in the event of low projected power would 
depend on other factors, such as the incidence and severity of side effects, 
cost, and results of other trials. 
PLANS FOR ANALYSIS 
Data Collected 
The schedule of CARET participant contacts is described in the Introduc- 
tion. The following data are collected: 
• First Visit: Basic demographics (age, gender, race, education, mobility), 
smoking history, occupational history, family cancer history, general health, 
health history, symptoms and signs, serum analytes, food frequency ques- 
tionnaire, reasons for participation, and (for asbestos-exposed participants 
only) American Thoracic Society (ATS) questionnaire for respiratory symp- 
toms [27], spirometry [28], and chest X ray. 
• Follow-up visits: Vital signs (height, weight, blood pressure), symptoms 
and signs, supplemental vitamin use, study vitamin adherence, reasons 
for not taking study vitamins (if participant has missed at least 10 capsules), 
general health, worry about health, updated cigarette-smoking history, 
actions taken by trial personnel to assist the participant to quit smoking, 
reasons for participating in the trial, effects on the participant of partici- 
pation, and perceptions of clinical improvements possibly related to the 
study vitamins. 
• Follow-up telephone calls: Symptoms and signs, supplemental vitamin use, 
reasons for not taking study vitamins, and new medical conditions. 
• Every 2 years: Food frequency, serum (annually for pilot participants), and 
(for asbestos-exposed partidpants only) ATS questionnaire and spirome- 
try. 
Inactive participants, who are no longer taking study vitamins, are con- 
tacted by telephone twice every year, at which times vital status, occurrence 
of any cancer, current smoking status, average number of cigarettes smoked 
per day, and general health are assessed. 
Blood Collection and Serum Analysis 
Sufficient blood to yield four 1.7-ml aliquots of serum is collected from 
pilot participants every year and from efficacy participants at their first visit 
and every 2 years after randomization. We collect an additional two 1.7-ml 
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aliquots of serum from a 12.5% cohort of participants for the CARET serum 
laboratory quality assurance. Serum aliquots are stored at -20°C at the study 
centers for up to 2 weeks prior to shipment in dry ice to the Coordinating 
Center, where they are then stored at - 70°C. The laboratory quality assurance 
includes participation in the National Institute of Standards and Technology 
round-robins and analysis of serum from standard pools with each run. In 
addition, 1 of every 10 samples ent to the laboratory for analysis is a masked 
split duplicate of another sample in that batch. The Coordinating Center 
monitors the performance on the split duplicates to assess within- and be- 
tween-run variability. Blood spots on Schleicher and Schuell no. 903 filter 
papers [29,30] will be obtained once in 1993 to save for DNA analyses by 
polymerase chain reaction methods as appropriate probes become available. 
For economy we have organized our analysis for the serum around the 
case-cohort method developed by Prentice [31]. The cohort analyzed for com- 
parison with the cases consists of all of the participants from the pilot studies 
and 10% of the efficacy participants, masked to the study centers and chosen 
independently of the 12.5% quality assurance cohort. One aliquot from each 
sample from the cohort will be analyzed as received for levels of retinol, 
retinyl palmitate, o~-carotene, and ~-carotene by a modification of the method 
of Milne and Botnen [32]. A single analysis typically uses 0.5-0.7 ml of serum; 
the remaining serum is refrozen at -70°C. Stored serum samples are also 
analyzed for those participants having trial outcomes. We will have approx- 
imately 7 controls per case for the lung cancer outcomes and 2.5 controls per 
case for the death outcomes. As a result, the case-cohort method has 90% of 
the efficiency for the detection of the effects of serum levels on lung cancer 
risk (75% for the effects on mortality risk) at only 20% of the cost, compared 
to analyzing serum on all participants. 
Data Analysis 
There are two specific aims of CARET: to test the efficacy of the study vita- 
mins in preventing lung cancer and to test the safety of our dosage of the study 
vitamins. The test of efficacy of the study vitamins is performed by a weighted 
log-rank statistic, stratified on study center, population (asbestos-exposed par- 
ticipants and heavy smokers), and cohort (pilots and efficacy). Lung cancers 
diagnosed in the first 2 years after randomization are down-weighted linearly 
to account for an expected time lag between starting to take the active vitamins 
and observation of the full chemopreventive effect due to the possibility of un- 
diagnosed lung tumors in some participants at randomization. Sample size for 
the weighted log-rank statistic is based on the method of Self et al. [33], modi- 
fied to account for the weighting in the computation of the variance of the test 
statistic (details available on request from the authors). 
The test of safety is performed by a comparison between the intervention 
groups in the trends and severity of relevant symptoms, signs, and liver 
function tests, using the method of Laird and Ware [34[. This test has greatest 
power for the specific alternative of a difference between arms in the slopes 
of the data, but should have adequate power to detect effects that plateau. 
Secondary analyses will examine the relationship between the study 
vitamins and the other outcomes (mesothelioma, other malignancies, and 
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death), and the adjustment of the primary and secondary analyses for po- 
tential covariates, including: 
• Lung cancer isk factors: age, gender, cigarette smoking history and ces- 
sation success, serum analyte levels, and asbestos exposure 
• For the asbestos-exposed population, baseline and follow-up measures of 
lung disease: X ray, spirometry, ATS questionnaire 
Secondary analyses will also be performed to better quantify the time pattern 
of any symptoms, signs, or abnormal aboratory measures found to be as- 
sociated with the intervention. The relationship between adherence and out- 
come measures is of interest; however, recent work by Efron and Feldman 
[35] points out that the parameters of greatest interest are not identifiable, 
and so can be estimated only by making untestable assumptions. 
Ancillary analyses will address the effect of the intervention on other trial 
measures and the associations among the measures. An example of the former 
is a test of the effect of the intervention in asbestos-exposed participants on 
lung function loss as assessed by the serial spirometries and the ATS ques- 
tionnaire. An example of the latter is the predictive power of baseline X rays 
on subsequent lung function loss. CARET will also have good power to ana- 
lyze effects of the intervention on cardiovascular outcomes, as noted above. 
CONCLUSION 
CARET is a major cancer chemoprevention trial testing the effects of 13-car- 
otene and retinyl palmitate on the incidence of lung cancer in individuals at 
high risk for the disease. We will randomize nearly 18,000 participants and amass 
over 100,000 person-years of follow-up to achieve our goal of 80% power to de- 
tect a maximal potential chemopreventive effect of 33% and an observable re- 
duction of 23% in lung cancer incidence. CARET, the Physicians Health Study 
[36], and the Alpha-Tocopherol Beta-Carotene Study [37] of 29,000 smokers in 
Finland are the National Cancer Institute's three major cancer chemopreven- 
tion trials utilizing 13-carotene plus vitamin A, 13-carotene alone, and 13-carotene 
plus vitamin E, respectively. We expect hese trials together to clarify the roles 
of these vitamins as cancer chemopreventive agents. 
Preventing cancer is preferable to needing to treat cancer. Epidemiological 
and animal studies have been valuable in identifying substances or activities 
that may help in preventing cancer. We must progress beyond the limitations 
of these studies to rigorous trials of such substances or activities, with pain- 
staking effort in design, recruitment, retention, and monitoring to achieve the 
designed power. When executed properly, prevention trials represent an es- 
sential test of the hypotheses generated by epidemiological studies with their 
potential for bias. Zelen [15] has argued that primary prevention trials for can- 
cer outcomes are not feasible; we are demonstrating with CARET that they are. 
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University of Maryland at Baltimore 
James Keogh, MD, Principal 
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Irvine Study Center 
University of California-Irvine 
Clinical Cancer Center 
Frank Meyskens, Jr., MD, Principal 
Investigator 
James Williams, Jr., MD, Medical 
Director 
Janis DeJohn, Study Manager 
New Haven Study Center 
CPS/CARET Occupational Health 
Center 
Lawrence & Memorial Hospital 
Mark R. Cullen, MD, Principal 
Investigator 
Martin Chemiack, MD, 
Co-principal Investigator 
Brenda Cartmel, PhD, Study 
Manager 
Portland Study Center 
Kaiser Permanente C nter for 
Health Research 
Barbara Valanis, DrPH, Principal 
Investigator 
Andrew Glass, MD, Co-principal 
Investigator 
Adrianne Feldstein, MD, 
Co-investigator 
Jan Blank, Study Manager 
San Francisco Study Center 
Asbestos Cancer Prevention Study 
San Francisco General Hospital 
John Balmes, Principal Investigator 
Cynthia Lotane, Study Manager 
Seattle Study Center 
Fred Hutchinson Cancer Research 
Center 
Gary Goodman, MD, Principal 
Investigator 
Corinne Powell, Study Manager 
Coordinating Center 
Fred Hutchinson Cancer Research 
Center 
Gilbert S. Omenn, MD, PhD, 
Principal Investigator 
James E. Grizzle, PhD, Director 
Bernedine Lund, MS, Study 
Manager 
